The lack of volume is actually quite normal and expected. This stock is awaiting an FDA approval, which would attract risk takers but deter safe investors. As the FDA approval looms closer, we're expecting some risk takers to buy more, but majority of investors will hold, neither selling or buying.
This is actually a rare benefit and what made this stock a rare gem for risk takers. Recent news about INNV should have their stock skyrocketting. The reason it is not, is again b/c many are not willing to take a risk with the FDA results. There will always be fewer risk takers than safe investors. So this kept the price low at 0.4 for others who wish to buy more or just discovered it.
There's always risk in life, there is no guarantee. But this stock so far is a good risk for high gain. You shouldn't pour your lifesaving into it, you shouldn't do that in any circumstance for any stock. However, if you are a risk taker, potential for reward in this case outweighs the risk since we already know the company has stabilized in recent news. We also know the FDA approval is not on a new product, but a new revision of a product that has already been selling.
If the FDA approves, risk takers will reap the reward. If it doesn't, then we have to look at the company as a whole without the FDA, which in the past news has been extremely positive, so even the safe investors will return. It won't be an explosive rise in this case, but it will be a steady rise.
Good luck, folks.
